Taris Biomedical LLC

Allergan, Inc.

Aventis Pharmaceuticals Inc.

Liris Biomedical, Inc.

Dennis Giesing

Michael John Cima

Cheryl Larrivee-Elkins

Paul D Goldenheim

Julie Himes

Purnanand Sarma

Heejin Lee

Emily Abbate

Sarah Hocking

Michael J Cima

Karen Danielle Daniel

Vikas Agarwal

Christopher Cutie

Gail H Hurst

Jessica K Anderson

Kin-Kai Hwang

Sarma Duddu

Christopher Searcy

Cheryl Larriveee-Elkins

The present application provides methods of treating overactive bladder and methods of training or retraining bladder, prolonging symptom relief, improving the quality of life and/or neuronal remodeling in an individual having overactive bladder, by administering an effective amount of trospium locally to the bladder of the individual for at least about 24 hours.

Methods of treating overactive bladder using trospium

Drug delivery devices and methods of administering drugs to patients are provided. A device includes a reservoir containing a drug. The reservoir is defined by a wall having a water-permeable portion, such that the water-permeable portion permits water to enter the device and contact the drug. A restraining plug closes off an opening of the device such that transient microchannels form between an elastic portion of the device and the restraining plug, upon the generation of a sufficient pressure within the reservoir, to release the drug from the device. Methods of treating patients for neurogenic detrusor overactivity resulting from a spinal cord injury and/or for idiopathic overactive bladder and urinary incontinence are also provided.

Drug delivery devices and methods for drug delivery

The present invention provides methods for treating or suppressing tumor metastasis at a site distinct from the bladder in an individual having a urothelial carcinoma of lower tract, comprising locally delivering to the bladder an effective amount of a chemotherapeutic agent (such as gemcitabine), wherein the chemotherapeutic agent is delivered continuously to the bladder for a sustained period of time (such as at least 24 hours).

Methods of treating tumor metastasis

Provided are methods of treating urothelial carcinomas of the lower tract comprising administering comprising administering gemcitabine continuously and locally to the bladder of an individual in an induction therapy and/or maintenance therapy.

Methods of treatment and maintenance therapy for bladder cancer using gemcitabine

Methods, devices, and medicaments that include trospium are provided for use in the treatment of bladder dysfunction by locally administering the trospium into the bladder to achieve a sustained concentration of trospium in urine in the bladder sufficient to produce a therapeutic concentration of trospium in bladder tissue. The drug may be delivered into the bladder from an intravesical drug delivery device inserted into the bladder, wherein the device continuously releases the drug into the urine in the bladder over an extended period of hours or days.

Drug delivery systems and methods for treatment of bladder dysfunction or disorder using trospium

Drug delivery devices and methods of administering drugs to patients are provided. A device () includes a reservoir () containing a drug (). The reservoir () is defined by a wall () having a water-permeable portion, such that the water-permeable portion permits water to enter the device () and contact the drug (). A restraining plug () closes off an opening of the device () such that transient microchannels () form between an elastic portion () of the device () and the restraining plug (), upon the generation of a sufficient pressure within the reservoir (), to release the drug () from the device (). Methods of treating patients for neurogenic detrusor overactivity resulting from a spinal cord injury and/or for idiopathic overactive bladder and urinary incontinence are also described.

In vivo drug delivery devices and methods for drug delivery

Devices and methods are provided for use in the treatment of bladder cancer by locally administering oxaliplatin into the bladder of a patient to achieve a sustained concentration of oxaliplatin in urine in the bladder sufficient to produce a therapeutic concentration of oxaliplatin in bladder tissue. The oxaliplatin may be delivered into the bladder from an intravesical drug delivery device inserted into the bladder, wherein the device continuously releases the oxaliplatin into the urine in the bladder over an extended period of hours or days.

Drug delivery devices and methods for treatment of bladder cancer with oxaliplatin

Devices and methods are provided for treating a patient having bladder pain and/or irritative voiding symptoms. The method includes administering to the patient's bladder lidocaine or another anesthetic agent continuously over a treatment period of 24 hours or more in an amount effective to achieve a therapeutic effect which is sustained beyond the end of the treatment period.

Devices and methods for sustained treatment of bladder pain and irritative voiding

Methods, devices, and medicaments that include oxaliplatin are provided for use in the treatment of bladder cancer by locally administering oxaliplatin into the bladder of a patient to achieve a sustained concentration of oxaliplatin in urine in the bladder sufficient to produce a therapeutic concentration of oxaliplatin in bladder tissue. The oxaliplatin may be delivered into the bladder from an intravesical drug delivery device inserted into the bladder, wherein the device continuously releases the oxaliplatin into the urine in the bladder over an extended period of hours or days.

Drug delivery systems and methods for treatment of bladder cancer

Methods, devices, and medicaments that include a drug are provided for use in the treatment of the prostate by locally administering the drug into the bladder of a patient to achieve a sustained concentration of the drug in urine in the bladder sufficient to produce a therapeutic concentration of the drug in the prostate. The drug may be delivered into the bladder from an intravesical drug delivery device inserted into the bladder, wherein the device continuously releases the drug into the urine in the bladder over an extended period of hours or days.

Growing community of inventors

Lee's Summit, MO, United States of America

Dennis Giesing